Search Results

There are 958 results for: content related to: Immune surveillance in multiple sclerosis patients treated with natalizumab

  1. Natalizumab for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald and John WD McDonald

    Published Online : 24 JAN 2007, DOI: 10.1002/14651858.CD006097.pub2

  2. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

    Inflammatory Bowel Diseases

    Volume 13, Issue 1, January 2007, Pages: 2–11, Bruce E. Sands, Richard Kozarek, Jack Spainhour, Charles F. Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Deborah Hilton and Stephen B. Hanauer

    Article first published online : 19 DEC 2006, DOI: 10.1002/ibd.20014

  3. You have free access to this content
    Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases

    CNS Drug Reviews

    Volume 13, Issue 1, March 2007, Pages: 79–95, Olaf Stüve and Jeffrey L. Bennett

    Article first published online : 24 APR 2007, DOI: 10.1111/j.1527-3458.2007.00003.x

  4. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 144–156, Nancy G. Wehner, George Shopp, Ingrid Osterburg, Antje Fuchs, Eberhard Buse and Janet Clarke

    Article first published online : 12 MAR 2009, DOI: 10.1002/bdrb.20193

  5. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 117–130, Nancy G. Wehner, George Shopp, Satoru Oneda and Janet Clarke

    Article first published online : 10 MAR 2009, DOI: 10.1002/bdrb.20190

  6. Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries

    European Journal of Neurology

    Volume 17, Issue 1, January 2010, Pages: 31–37, N. Putzki, O. Yaldizli, M. Mäurer, S. Cursiefen, S. Kuckert, C. Klawe, M. Maschke, B. Tettenborn and V. Limmroth

    Article first published online : 9 JUL 2009, DOI: 10.1111/j.1468-1331.2009.02728.x

  7. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years

    European Journal of Neurology

    Volume 23, Issue 6, June 2016, Pages: 1101–1109, R. Zivadinov, D. Hojnacki, N. Bergsland, C. Kennedy, J. Hagemeier, R. Melia, D. P. Ramasamy, J. Durfee, E. Carl, M. G. Dwyer and B. Weinstock-Guttman

    Article first published online : 21 MAR 2016, DOI: 10.1111/ene.12992

  8. You have full text access to this OnlineOpen article
    Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 4, April 2015, Pages: 373–387, Timothy Spelman, Tomas Kalincik, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Ludwig Kappos, Larisa Tsvetkova, Shibeshih Belachew, Robert Hyde, Freek Verheul, Francois Grand-Maison, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Alessandra Lugaresi, Jeannette Lechner-Scott, Celia Oreja-Guevara, Raymond Hupperts, Thor Petersen, Michael Barnett, Maria Trojano, Helmut Butzkueven and on behalf of the MSBase Investigators and the TOP investigators

    Article first published online : 27 FEB 2015, DOI: 10.1002/acn3.180

  9. Crohn's Disease

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 15 SEP 2006, DOI: 10.1002/9780470041000.cedt019

  10. You have free access to this content
    The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

    British Journal of Haematology

    Volume 155, Issue 4, November 2011, Pages: 438–448, Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, Giovanni Tonon, Ursula Hainz, Yu-Tzu Tai, Sonia Vallet, Niels Halama, Dirk Jäger, Dian L. Olson, Martin Sattler, Dharminder Chauhan and Kenneth C. Anderson

    Article first published online : 19 SEP 2011, DOI: 10.1111/j.1365-2141.2011.08864.x

  11. Effects of natalizumab, an α4 integrin inhibitor, on the development of Hartley guinea pigs

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 98–107, Nancy G. Wehner, George Shopp, Meredith S. Rocca and Janet Clarke

    Article first published online : 17 MAR 2009, DOI: 10.1002/bdrb.20189

  12. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study

    Acta Neurologica Scandinavica

    Volume 126, Issue 5, November 2012, Pages: 306–314, R. Lanzillo, M. Quarantelli, S. Bonavita, G. Ventrella, G. Lus, G. Vacca, A. Prinster, G. Orefice, G. Tedeschi and V. Brescia Morra

    Article first published online : 23 NOV 2011, DOI: 10.1111/j.1600-0404.2011.01622.x

  13. Effects of natalizumab, an α4 integrin inhibitor, on fertility in male and female guinea pigs

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 86, Issue 2, April 2009, Pages: 108–116, Nancy G. Wehner, Michael Skov, George Shopp, Meredith S. Rocca and Janet Clarke

    Article first published online : 12 MAR 2009, DOI: 10.1002/bdrb.20191

  14. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis

    The Journal of Clinical Pharmacology

    Tatiana Plavina, Edward J. Fox, Nisha Lucas, Kumar Kandadi Muralidharan and Daniel Mikol

    Article first published online : 3 MAR 2016, DOI: 10.1002/jcph.707

  15. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 87–94, S. Rossi, C. Motta, V. Studer, V. De Chiara, F. Barbieri, F. Monteleone, A. Fornasiero, G. Coarelli, G. Bernardi, G. Cutter, O. Stüve, M. Salvetti and D. Centonze

    Article first published online : 28 JUN 2012, DOI: 10.1111/j.1468-1331.2012.03794.x

  16. You have free access to this content
    Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

    Intervention Review

    The Cochrane Library

    Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher and Georgia Salanti

    Published Online : 6 JUN 2013, DOI: 10.1002/14651858.CD008933.pub2

  17. Health-related quality of life in multiple sclerosis: effects of natalizumab

    Annals of Neurology

    Volume 62, Issue 4, October 2007, Pages: 335–346, Richard A. Rudick, Deborah Miller, Steve Hass, Michael Hutchinson, Peter A. Calabresi, Christian Confavreux, Steven L. Galetta, Gavin Giovannoni, Eva Havrdova, Ludwig Kappos, Fred D. Lublin, David H. Miller, Paul W. O'Connor, J. Theodore Phillips, Chris H. Polman, Ernst-Wilhelm Radue, William H. Stuart, Andrzej Wajgt, Bianca Weinstock-Guttman, Daniel R. Wynn, Frances Lynn and Michael A. Panzara

    Article first published online : 14 AUG 2007, DOI: 10.1002/ana.21163

  18. What to expect after natalizumab cessation in a real-life setting

    Acta Neurologica Scandinavica

    Volume 130, Issue 2, August 2014, Pages: 97–102, S. Salhofer-Polanyi, A. Baumgartner, J. Kraus, E. Maida, M. Schmied and F. Leutmezer, The Austrian Tysabri Registry Group

    Article first published online : 10 APR 2014, DOI: 10.1111/ane.12250

  19. Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2203–2208, S.V. Kane, S. Horst, W.J. Sandborn, B. Becker, B. Neis, M. Moscandrew, K.A. Hanson, W.J. Tremaine, D.H. Bruining, W.A. Faubion, D.S. Pardi, W.S. Harmsen, A.R. Zinsmeister and E.V. Loftus

    Article first published online : 14 MAR 2012, DOI: 10.1002/ibd.22943

  20. You have free access to this content
    Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance

    British Journal of Haematology

    Volume 155, Issue 1, October 2011, Pages: 53–64, Marek Mraz, Clive S. Zent, Amy K. Church, Diane F. Jelinek, Xiaosheng Wu, Sarka Pospisilova, Stephen M. Ansell, Anne J. Novak, Neil E. Kay, Thomas E. Witzig and Grzegorz S. Nowakowski

    Article first published online : 12 JUL 2011, DOI: 10.1111/j.1365-2141.2011.08794.x